The impact of disease severity on the informed consent process in clinical research

American Journal of Medicine

Volumn 100, Issue 3, 1996, Pages 261-268

  Schaeffer, Monica H ^a   Krantz, David S ^d   Wichman, Alison ^b   Masur, Henry ^a   Reed, Eddie ^c   Vinicky, Janicemarie K ^e  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^e WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; PACLITAXEL; TETRAPLATIN; ZIDOVUDINE;

ADULT; AGED; ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFIDENTIALITY; DEMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HISTOLOGY; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMED CONSENT; LYMPHOCYTE COUNT; MALE; MEDICAL INFORMATION; METASTASIS; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUESTIONNAIRE; RISK;

EID: 0029927575     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)89483-1     Document Type: Article

References (30)

1. Meisel A, Roth CH. Toward an informed discussion of informed consent: a review and critique of the empirical studies. Arizona Law Rev. 1983;25: 265-346.
2. Stanley B, Sieber J, Melton G. Empirical studies of ethical issues in research: a research agenda. Am Psychol. 1987;42:735-741.
3. Sutherland HJ, Lockwood GA, Till JE. Are we getting informed consent from patients with cancer? J R Soc Med. 1990;83:439-443.
4. Faden RP, Beauchamp TL. A History and Theory of Informed Consent. New York: Oxford University Press; 1986:298-336.
5. Schultz AL, Pardee GP, Ensinck JW. Are research subjects really informed? West J Med 1975;123:76-80.
6. Cassileth BR, Zupkis RB, Sutton-Smith K, March V. Informed consent - why are its goals imperfectly realized? NEJM. 1980;302:896-900.
7. Mariner WK, McArdle P. Consent forms, readability, and comprehension: the need for new assessment tools. Law Med Health Care. 1985;13:68-74.
8. Kennedy B, Lillehaugen A. Patient recall of informed consent. Med Pediatr Oncol. 1979;7:173-189.
9. Parker RJ, Vionnet JA, Bostick-Bruton F, Reed E. Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin. Cancer Res. 1993;53:242-247.
10. Christian MC, Spriggs D, Tutsch KD, et al. Phase I trials with ormaplatin (tetraplatin). In: Howell S, ed. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. New York: Plenum Press; 1992: 453-458.
11. Bicher A, Kohn E, Sarosy G, et al. The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose intense taxol and G-CSF. Anticancer Drugs. 1993;4:141-148.
12. Lane CH, Herpin B, Banks S, et al. Zidovudine vs. alpha interferon vs. the combination in patients with early HIV infection. Abstracts of the VIII International Conference on AIDS; July 19-24, 1992; Amsterdam, The Netherlands.
13. Cockrell RJ, Folstein MF. Mini-Mental State Examination (MMSE). Psychopharmacol Bull. 1988;24:689-692.
14. Krantz DS, Baum A, Wideman M. Assessment of preferences for self-treatment and information in health care. J Pers Soc Psychol. 1980;39: 977-990.
15. Department of Health and Human Services. Regulations for protection of human subjects. 45 CFR 46, 1981.
16. Zuckerman C, Lubin R. The Multiple Affect Adjective Checklist. Today form. New Jersey Educational Services, 1965.
17. Rasinski TV. Botel Reading Inventory. In: Keyser DJ, Sweetland RC, eds. Test Critiques. Vol. 5. Kansas City: Test Corporation of America; 1986:37-42.
18. RightWriter 5.0 for DOS. Carnel, Ind: Que Software, Prentice Hall Computer Publishing; 1992.
19. Winer BJ, ed. Statistical Principles in Experimental Design. 2nd ed. New York: McGraw-Hill; 1962:198.
20. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. 44 Federal Register 76 (April 18, 1979). Washington, DC: U.S. Government Printing Office; 1988.
21. Lidz CW, Appelbaum PS, Meisel A. Two models of implementing informed consent. Arch Intern Med. 1988;148:1385-1389.
22. Rimer B, Jones W, Keintz M, et al. Informed consent: a crucial step in cancer patient education. Health Educ Q. 1984:30-41.
23. Riecken HW, Ravich R. Informed consent to biomedical research in Veterans Administration Hospitals. JAMA. 1982;248(pt 3):344-348.
24. Lentz SL. Confidentiality and informed consent and the acquired immunodeficiency syndrome epidemic. Arch Pathol Lab Med. 1990;114: 304-308.
25. Lo B. Ethical dilemmas in HIV infection: what have we learned? Law Med Health Care. 1992;20:92-103.
26. Susman EJ, Dorn LD, Fletcher JC. Participation in biomedical research: the consent process as viewed by children, adolescents, young adults, and physicians. J Pediatr. 1992;121:547-552.
27. Faden RR, Becker C, Lewis C, et al. Disclosure of information to patients in medical care. Med Care. 1981;19(pt 7):718-733.
28. Leventhal H. Findings and theory in the study of fear communications. In: Berkowitz L, ed. Advances in Experimental Social Psychology. New York: Academic Press; 1970:119-186.
29. Appelbaum PS, Roth LH, Lidz C. The therapeutic misconception: informed consent in psychiatric research, Int J Law Psychiatry. 1982;5:319-329.
30. Appelbaum PS, Grisso T. Assessing patients' capacities to consent to treatment. NEJM. 1988;319:1635-1638.